Key Levels:
Support: 360 to 350
Resistance: 389, 399, 421
Key Drivers:
Sun Pharma Advanced Research Company Ltd focuses on R&D of pharmaceutical products, earning revenue from license fees, royalties, and R&D services. In FY23, it obtained USFDA approval for Sezaby and filed for NDA of PDP-716 in collaboration with Visiox Pharma. The company primarily targets oncology & neurodegeneration, with 8 pipeline assets in various stages. It has shifted focus from New Drug Delivery Systems to New Chemical Entities, investing heavily in R&D. SPARC is part of the SunPharma Group, with significant corporate backing. It faced an IT security incident in March 2023, though business operations were not directly impacted. The company plans Phase 1 studies for SCD-153 and SBO-154 in FY24 and FY25, respectively, aiming for continued growth through collaborations and new preclinical programs.
Support: 360 to 350
Resistance: 389, 399, 421
Key Drivers:
Sun Pharma Advanced Research Company Ltd focuses on R&D of pharmaceutical products, earning revenue from license fees, royalties, and R&D services. In FY23, it obtained USFDA approval for Sezaby and filed for NDA of PDP-716 in collaboration with Visiox Pharma. The company primarily targets oncology & neurodegeneration, with 8 pipeline assets in various stages. It has shifted focus from New Drug Delivery Systems to New Chemical Entities, investing heavily in R&D. SPARC is part of the SunPharma Group, with significant corporate backing. It faced an IT security incident in March 2023, though business operations were not directly impacted. The company plans Phase 1 studies for SCD-153 and SBO-154 in FY24 and FY25, respectively, aiming for continued growth through collaborations and new preclinical programs.
Trade active
Broken both the resistance and now again getting started to get the final resistance
Regards
SuperChartz
telegram.me/SuperChartz
Instagram.com/SuperChartz
facebook.com/SuperChartz
twitter.com/SuperChartz
youtube.com/@SuperChart
Get TradingView Premium 👇
in.tradingview.com/?aff_id=130166
SuperChartz
telegram.me/SuperChartz
Instagram.com/SuperChartz
facebook.com/SuperChartz
twitter.com/SuperChartz
youtube.com/@SuperChart
Get TradingView Premium 👇
in.tradingview.com/?aff_id=130166
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Regards
SuperChartz
telegram.me/SuperChartz
Instagram.com/SuperChartz
facebook.com/SuperChartz
twitter.com/SuperChartz
youtube.com/@SuperChart
Get TradingView Premium 👇
in.tradingview.com/?aff_id=130166
SuperChartz
telegram.me/SuperChartz
Instagram.com/SuperChartz
facebook.com/SuperChartz
twitter.com/SuperChartz
youtube.com/@SuperChart
Get TradingView Premium 👇
in.tradingview.com/?aff_id=130166
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.